There is more innovation in cancer research today than ever before. Many of these efforts are disjointed and silo-ed and as a result often do not reach their full potential. If we can capture that potential, we believe it could greatly benefit cancer patients.

Cullinan uniquely applies open innovation to the development of scientific oncology assets. Our approach breaks down silos, encourages new ways of thinking and collaboration, and ultimately turns ideas and inspiration into novel executable therapeutic concepts. Through both internal and external means, we seek to develop assets that have the potential to dramatically improve the lives of those living with cancer.

Drug development through
the prism of modern-day
portfolio management.

Our Approach

Cullinan Oncology, Inc. is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.

Our strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that we believe have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.

Cullinan Development Engine


At the core of any great company is its people. The Cullinan team is a group of accomplished professionals that share a vision for eradicating cancer.

Nadim Ahmed
Nadim AhmedPresident and Chief Executive Officer
Patrick Baeuerle, Ph.D.
Patrick Baeuerle, Ph.D.Co-Founder, Acting Chief Scientific Officer, Biologics
Bianca Boschmans
Bianca BoschmansManager, Financial Reporting
Myles Clancy
Myles ClancySenior Director, Clinical Operations
Anthony Davis
Anthony DavisExecutive Director, Head of Quality Assurance
Parissa Elwood
Parissa ElwoodSenior Associate, R&D Operations
John Janik
John JanikVice President, Clinical Development
Sandeep Kaur
Sandeep KaurSenior Clinical Trial Manager, Clinical Operations
Raymond T. Keane, Esq.
Raymond T. Keane, Esq.Chief Legal Officer
Bochong Li, Ph.D., J.D.
Bochong Li, Ph.D., J.D.Director, Innovation
Kristan Meetze, Ph.D.
Kristan Meetze, Ph.D.Vice President, Preclinical and Early Development
Naveen Mehta, Ph.D.
Naveen Mehta, Ph.D.Director, Preclinical R&D
Mark Melville
Mark MelvilleVice President of CMC, Biologics
Jennifer Michaelson, Ph.D.
Jennifer Michaelson, Ph.D.Chief Development Officer, Biologics
Jenny Moore
Jenny Moore Corporate Counsel
Kelley Nguyen
Kelley NguyenSenior Manager of Finance
Nate Nguyen
Nate NguyenDirector of Accounting, Controller
Asher Page, Ph.D.
Asher Page, Ph.D.Director, Business Development and Licensing
Nancy Parris
Nancy ParrisExecutive Assistant
Erica Player
Erica PlayerExecutive Assistant and Office Supervisor
Kavya Rakhra
Kavya RakhraAssociate Director, Preclinical R&D
Corinne Savill, Ph.D.
Corinne Savill, Ph.D.Acting Chief Business Officer
Irina Shapiro, Ph.D.
Irina Shapiro, Ph.D.Executive Director, Head of Translational Research, Biologics
Lori Thompson
Lori ThompsonExecutive Assistant
Jeff Trigilio
Jeff TrigilioChief Financial Officer
Natasha Uzelac
Natasha UzelacSenior Director, Head of Analytical Sciences
Matthew Weber
Matthew WeberDirector, Program Management
Kerry Whalen
Kerry WhalenSenior Director, Preclinical and Early Development
David Witter, Ph.D.
David Witter, Ph.D.Vice President, Preclinical Research
Hector Zaanoni
Hector ZaanoniDirector, CMC
Leigh Zawel, Ph.D.
Leigh Zawel, Ph.D.Chief Scientific Officer, Small Molecules


Owen Hughes
Owen HughesSenior Advisor
Briggs Morrison, M.D.
Briggs Morrison, M.D.Clinical Advisor
Jon Wigginton, M.D.
Jon Wigginton, M.D.Senior Advisor & Chairman of SAB

Board of Directors

Nadim Ahmed
Nadim Ahmed
Thomas Ebeling
Thomas Ebeling
Ansbert Gadicke, M.D.
Ansbert Gadicke, M.D.
Tony Rosenberg
Tony Rosenberg
Stephen Webster
Stephen Webster